Aspen Pharmacare has received regulatory approval for its generic injectable semaglutide in both Brazil and South Africa, the company said in an announcement released on the JSE’s SENS service at 09:00 on 11 November 2026. Approval for the product had already been received in Canada, as the company announced in July 2026, and Aspen says commercialisation is expected to begin in Canada, Brazil and South Africa over the next few months.
The approval is for type 2 diabetes, not weight loss
The wording of the announcement matters. Aspen says semaglutide is indicated, together with diet and exercise, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. That is the diabetes indication. The announcement does not mention obesity or weight management, which is the use that has driven public attention to this class of medicine.
The announcement is short. It does not give a launch date, a price, the strength or presentation of the product, the name of the originator medicine it copies, or any estimate of sales. Each of those would change how much the approval is worth to Aspen and to patients.
Three markets, one product
Aspen describes the three approvals as one product receiving clearance in three countries: Canada in July, then Brazil and South Africa on this announcement. The company does not say whether the Brazilian and South African approvals came from the regulators on the same day, only that Aspen has received them.
Aspen’s own website says the group supplies medicines to more than 100 countries through 57 offices in some 41 countries and territories, and that it has 24 manufacturing facilities across 13 sites. Injectables is one of its named business segments, alongside prescription and over the counter medicines. The company’s site does not say where this product will be made or filled, and the SENS does not either.
What is known about demand in South Africa
The demand backdrop comes from earlier reporting rather than from Aspen’s announcement. Our report on the Obiflex buy now, pay later offer for GLP-1 medicines cited Moneyweb as saying these medicines cost between R2 500 and R6 000 a month depending on the dose, and cited Moneyweb and Bloomberg as saying Aspen distributes Eli Lilly’s Mounjaro locally and has applied to make a generic semaglutide. Those figures are not in the SENS and we have not confirmed them against Aspen’s own documents.
Prices in this market also move by regulation. As we reported when the single exit price rose by 2.88% from 1 October, private sector medicine prices are set by the state, and the industry argues that cost pressure from the weaker rand and imported ingredients has been squeezing manufacturers. Aspen has not said what price it will seek for the new generic.
What it means for business
Our reading: for Aspen, the approvals turn a product from a regulatory application into something it can sell, which is the step that comes before revenue. Aspen’s chief executive has said in the past that these medicines could become its largest product category, according to the reports cited above, though that is his view and not a figure in this announcement.
For employers and medical schemes in South Africa, the question is cost. Our earlier report noted that medical schemes are generally not obliged to pay for GLP-1 medicines used for weight loss, so a cheaper generic could matter most to patients paying out of pocket. Whether it does depends on pricing, and on whether the approved diabetes indication is the only one doctors may prescribe it for.
What is still unknown
The announcement leaves several questions open. It does not say what the product will cost, when it reaches pharmacy shelves in South Africa, or how much Aspen expects to sell. It does not say how many other generic versions have been approved locally or are waiting. Nor does it say whether the approval carries any conditions, such as post approval commitments to the regulator.
Until Aspen publishes those details on its investor relations page, the approval is a regulatory milestone with no financial figures attached.
